联川生物×10x Genomics×百曜科技签署三方战略合作协议，共建AI虚拟细胞新型基础设施
2026年9月24日，杭州联川生物技术股份有限公司（以下简称“联川生物”）、10x Genomics与百曜（北京）科技有限公司（以下简称“百曜科技”）三方战略合作签约仪式在杭州举行。三方计划围绕AI虚拟细胞（AI Virtual Cell, AIVC）共建“数据—模型—实验”闭环，推动其成为AI时代药物开发的新型基础设施。
三方此番携手，意在破解AIVC从前沿概念迈向产业应用的难题。10x Genomics以全球领先的单细胞与空间组学技术为源头，联川生物以AI-Ready标准化数据能力为底座，百曜科技以AIVC模型平台为引擎，协同共建AIVC数据标准。每一次实验的结果都将回流反哺模型迭代，推动药物开发从依赖试错的经验学科，转向可模拟、可预测的精确科学。
（从左至右：联川生物董事长兼总经理郎秋蕾，10x Genomics联合创始人、总裁兼首席科学官Ben Hindson，百曜科技创始人李鑫）
各方致辞：共话AI虚拟细胞新范式
签约仪式上，三方企业代表依次致辞，围绕行业趋势与企业核心能力，展望了合作价值与未来规划。
联川生物董事长兼总经理郎秋蕾表示，高性能AI模型的上限由高质量的数据决定，而高质量数据的规模化标准化生产能力，正是联川生物不可替代的优势。公司长期践行AI-Ready Data Infrastructure理念，已累计完成数万例单细胞项目和数千例空间组学项目，形成了AI-Ready标准化数据生产能力，为各类模型提供高质量训练语料。三方将建立常态化协作机制，让技术、实验、模型串成一条可复用的新药研发路径。
（联川生物董事长兼总经理郎秋蕾致辞）
10x Genomics联合创始人、总裁兼首席科学官Ben Hindson表示，高质量的生物学数据对于构建能够可靠预测细胞和组织行为的AI模型至关重要。我们非常高兴能与联川生物及百曜科技携手合作，共同推进生物学研究与新药研发。
（10x Genomics联合创始人、总裁兼首席科学官Ben Hindson致辞）
百曜科技创始人李鑫表示，百曜科技已基于AURA CellOS构建覆盖数据、模型、智能体与干湿闭环的全栈能力，将在三方合作中发挥模型训练与算法开发优势，推动实测组学数据转化为可训练、可验证、可应用的AIVC模型能力。未来，百曜科技将与 10x Genomics 的单细胞及空间组学技术平台、联川生物的多组学数据生产与科研服务能力形成协同，共同打通从高质量数据生成、模型训练迭代到应用验证的完整链路，推动 AIVC 从模型研发走向可调用、可验证、可辅助决策的实际应用。
（百曜科技创始人李鑫致辞）
签约仪式结束后，三方核心技术与管理团队随即展开深度座谈，就后续各项合作细节进行深入讨论。
（三方团队现场交流）
行业意义
本次三方战略合作的落地，标志着前沿组学技术、高质量组学数据与AI虚拟细胞模型的深度融合。AI虚拟细胞不再只是一个前沿概念——它正在成为药物开发的新型基础设施，也是一条刚刚开启的新赛道。
关于联川生物
杭州联川生物技术股份有限公司成立于2006年，是国家级专精特新"小巨人"企业。公司围绕中心法则提供全组学服务，覆盖基因组与微生物组、转录组、表观组、蛋白质组、代谢组及单细胞时空多组学；在基因"读—写—改"方向掌握底层核心技术，自主研发 μParaFlo™ 光敏酸微流控DNA合成平台，用于抗体药物开发、靶向基因捕获、基因编辑文库等方向。公司践行AI-Ready Data Infrastructure 理念，具备标准化、规模化的高质量大数据生产能力。
关于百曜科技
百曜科技是中国首家原生 AI 虚拟细胞（AIVC）平台公司，致力于构建下一代生命科学领域的基础设施，让生命系统可模拟、可预测、可设计。
关于10x Genomics
10x Genomics是一家生命科学科技公司，致力于开发加速生命奥秘探索、推动人类健康进步的产品。提供的集成式研究解决方案包括用于单细胞和空间生物学的仪器、耗材及软件，帮助学术研究人员、转化医学研究者以及生物制药公司以与生物学复杂性相匹配的分辨率和规模理解生物系统。其产品推动了肿瘤学、免疫学、神经科学等领域的突破性进展，助力重大发现不断涌现，正在改变人类对健康和疾病的认知。
On September 24, 2026, LC-Bio Technologies (Hangzhou) Co., Ltd. (“LC-Bio”), 10x Genomics, and Vitaura (Beijing) Technology Co., Ltd. (“Vitaura”) held a signing ceremony in Hangzhou to formalize a three-party strategic cooperation agreement. The three companiesintend towilljointly build a “data–model–experiment” loop around AI virtual cells (AIVC), establishing it as foundational infrastructure for drug discovery in the AI era.
The partnership is designed to address the central challenge facing AIVC — moving it from a frontier concept to real industrial application. 10x Genomics contributes world-leading single-cell and spatial omics technology as the source; LC-Bio brings AI-ready, standardized data capabilities as the foundation; and Vitaura supplies its AIVC modeling platform as the core engine. Together, the threeintend towillco-develop data standards for AIVC. Results from every experiment will feed back into model iteration, shifting drug discovery from a trial-and-error discipline toward a predictive science that can be simulated before it is tested.
（From left to right:Julie Lang, Chairwoman and CEO of LC-Bio，Ben Hindson, Co-Founder, President and Chief Scientific Officer of 10x Genomics, Li Xin, Founder and CEO of Vitaura）
Opening Remarks: Charting a New Paradigm for AI Virtual Cells
At the ceremony, senior representatives from all three companies spoke in turn, assessing industry trends and each company’s core capabilities, and laying out both the value of the partnership and their plans for what comes next.
Julie Lang, Chairwoman and CEO of LC-Bio, said the ceiling of any high-performance AI model is set by the quality of the data behind it — and that the ability to produce high-quality data at scale and to a consistent standard is precisely LC-Bio’s irreplaceable advantage. The company has long applied the AI-Ready Data Infrastructure principle and has completed tens of thousands of single-cell projects and thousands of spatial omics projects, building an AI-ready, standardized data production capability that supplies high-quality training corpora for models of all kinds. The three parties will establish a standing collaboration framework that connects technology, experimentation, and modeling into a reusable pathway for drug discovery.
(Julie Lang, Chairwoman and CEO of LC-Bio, delivering her remarks.)
Ben Hindson, Co-Founder, President and Chief Scientific Officer of 10x Genomics, said,“High-quality biological data are essential to building AI models that can reliably predict how cells and tissues behave. We are excited to work with LB-Bio and Vitaura to advance biological research and drug discovery.”
(Ben Hindson, Co-Founder, President and Chief Scientific Officer of 10x Genomics, delivering remarks.)
Xin Li, Founder of Vitaura, said: “Built on AURA CellOS, Vitaura has developed full-stack capabilities spanning data, models, AI agents, and closed-loop integration of computational and wet-lab workflows. Through this partnership, we will leverage our strengths in model training and algorithm development to turn experimentally generated omics data into AIVC models that can be trained, validated, and deployed in real-world applications. Going forward, we will combine our capabilities with 10x Genomics’ single-cell and spatial omics platforms and LC-Bio’s multi-omics data generation and research services. Together, we aim to establish an end-to-end workflow encompassing high-quality data generation, iterative model training, and application validation—accelerating the translation of AIVC from model development into deployable and verifiable tools that support real-world decision-making.”
(Figure 4: Li Xin, Founder of Vitaura, delivering remarks.)
After the ceremony, the core technical and management teams from all three companies moved into an in-depth working session to work through the details of the collaboration going forward.
(Teams from the three companies in discussion.)
Industry Significance
The launch of this three-party strategic cooperation marks a deep integration of frontier omics technology, high-quality omics data, and AI virtual cell models. AIVC is no longer merely a frontier concept — it is becoming foundational infrastructure for drug discovery, and a new frontier that has only just opened.
About LC-Bio
LC-Bio Technology Co., Ltd. was founded in 2006 with a global R&D center in Houston, USA. LC-Bio provides multi omics services including genomics, transcriptomics, epigenomics, proteomics, metabolomics, and single-cell and spatial multi-omics. For reading, writing, and editing genes — the foundational layer of the field — the company has developed its own μParaFlo™ light-directed microfluidic DNA synthesis platform, capable of synthesizing tens of thousands of oligonucleotides in parallel. Embracing the AI‑Ready Data Infrastructure concept, the company boasts standardized and large-scale capacity to generate high-quality biological big data.
About Vitaura
Vitaura is China’s first AI-native virtual cell (AIVC) platform company. It is building next-generation infrastructure for the life sciences, making living systems possible to simulate, predict, and design.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. The integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. The products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease.